Elite Pharmaceuticals, Inc., a health care company based in Northvale, United States, has been actively engaged in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products. The company’s focus spans across various therapeutic areas, including cardiovascular, antidiabetic, anti-infective agents, as well as cough and cold preparations. Currently, Elite Pharmaceuticals is advancing its portfolio with pain products that are in clinical trials, showcasing its commitment to addressing diverse medical needs.
As of April 23, 2026, the company’s stock is traded on the OTC Bulletin Board, with a close price of $0.36. This represents a significant fluctuation over the past year, with a 52-week high of $0.82 recorded on June 17, 2025, and a 52-week low of $0.35 on March 31, 2026. The market capitalization of Elite Pharmaceuticals stands at approximately $391.36 million, reflecting its valuation in the competitive pharmaceutical sector.
The company’s financial metrics indicate a price-to-earnings ratio of 10.24, suggesting investor expectations regarding its future earnings growth. Since its public offering on July 23, 1998, Elite Pharmaceuticals has maintained its presence in the health care sector, particularly within the pharmaceutical industry, by continuously innovating and expanding its product offerings.
For stakeholders and interested parties seeking further information about Elite Pharmaceuticals’ activities and offerings, the company maintains an online presence through its website, www.elitepharma.com . This platform provides insights into their ongoing projects, clinical trials, and strategic initiatives aimed at enhancing their market position and delivering value to patients and shareholders alike.
